Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade F 1.79 -4.28% -0.08
AEZS closed down 4.28 percent on Friday, September 13, 2019, on 1.3 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AEZS trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.28%
Narrow Range Bar Range Contraction -4.28%
NR7 Range Contraction -4.28%
Inside Day Range Contraction -4.28%
Wide Bands Range Expansion -4.28%
Oversold Stochastic Weakness -4.28%
Oversold Stochastic Weakness -3.76%
Bullish Engulfing Bullish -3.76%

Older signals for AEZS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Chemistry Biopharmaceutical Cancer Treatment Of Cancer Oncology Solid Tumors Prostate Cancer Lymphoma Peptides Neuroblastoma Glioma Treatment Of Prostate Cancer Anthracyclines Gnrh Antagonists Endometrial Cancer In Vitro Fertilization Ozarelix
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.57
52 Week Low 1.29
Average Volume 85,503
200-Day Moving Average 3.2699
50-Day Moving Average 2.2978
20-Day Moving Average 2.0055
10-Day Moving Average 1.909
Average True Range 0.1542
ADX 29.24
+DI 16.3586
-DI 27.7461
Chandelier Exit (Long, 3 ATRs ) 2.1074
Chandelier Exit (Short, 3 ATRs ) 2.2226
Upper Bollinger Band 2.3224
Lower Bollinger Band 1.6886
Percent B (%b) 0.16
BandWidth 31.603091
MACD Line -0.1401
MACD Signal Line -0.1319
MACD Histogram -0.0082
Fundamentals Value
Market Cap 28.84 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -1.05
Price-to-Sales 28.12
Price-to-Book 6.12
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.93
Resistance 3 (R3) 1.95 1.92 1.91
Resistance 2 (R2) 1.92 1.88 1.91 1.90
Resistance 1 (R1) 1.85 1.86 1.84 1.84 1.89
Pivot Point 1.82 1.82 1.81 1.81 1.82
Support 1 (S1) 1.76 1.79 1.74 1.74 1.69
Support 2 (S2) 1.73 1.76 1.72 1.68
Support 3 (S3) 1.66 1.73 1.67
Support 4 (S4) 1.65